Magnesium-ibogaine therapy in veterans with traumatic brain injuries

Traumatic brain injury (TBI) produces persistent functional, cognitive and psychiatric sequelae, including post-traumatic stress disorder (PTSD), depression and anxiety, and these complications are common among Special Operations Forces veterans (SOVs). Previous research has explored ibogaine—an oneirogenic alkaloid derived from Tabernanthe iboga—primarily as a treatment for substance use disorders, and case reports and anecdotal accounts have suggested mood and functional benefits. Safety concerns, however, notably QT interval prolongation and rare fatal arrhythmias, have limited research; magnesium supplementation has been proposed as a potential cardioprotective co-treatment because it can reduce QT interval prolongation from other medications. Cherian and colleagues set out to provide initial prospective data on an integrated magnesium‑ibogaine protocol (the Stanford Traumatic Injury to the CNS protocol, MISTIC) in SOVs with predominantly mild TBI. The study aimed to assess changes in global functioning (primary outcome: WHODAS‑2.0) immediately after treatment and at 1 month, and to measure clinician-rated PTSD, depression and anxiety as secondary outcomes, together with safety, neuropsychological performance and exploratory analyses of suicidality and remission/response rates.

This was a prospective observational study of 30 male SOVs who independently sought ibogaine treatment at Ambio Life Sciences (Mexico) and were referred to the Stanford study team for research follow‑up. Thirty of 33 initially enrolled participants completed baseline and posttreatment assessments between November 2021 and September 2022. Inclusion criteria included US veteran status, age 18–70, history of head trauma and ability to consent and attend study visits; exclusion criteria included psychotic history, active high suicide risk, significant cardiovascular, hepatic or renal disease, pregnancy and other conditions judged unsafe. The study was approved by Stanford's IRB, informed consent was obtained and the trial was preregistered (ClinicalTrials.gov NCT04313712). Procedures combined remote baseline evaluations with in‑person assessments at Stanford 2–3 days before treatment, travel to the Ambio clinic for the MISTIC protocol and return assessments 4–5 days posttreatment and at 1 month. Participants received pre‑ and posttreatment coaching arranged by a veteran nonprofit; additional on‑site wellness activities (sweat lodge, yoga, breathwork, massage, etc.) were available, but no psychotherapy was provided during the acute treatment. Baseline diagnostic interviews and measures included the MINI/SCID, the Ohio State University TBI screen, the Boston Assessment of TBI‑Lifetime and the Combat Exposure Scale (CES). MISTIC dosing and monitoring were conducted by Ambio clinical staff. An intravenous infusion of 1 g magnesium sulfate and an oral gastroprotective agent was given 1–2 h before the initial oral ibogaine test dose (2–3 mg kg‑1); additional oral doses could be given within ~40 min up to a total <14 mg kg‑1 over a 2‑h period. Approximately 12 h after ibogaine administration participants received a further IV magnesium dose and antioxidant/metabolic support. Continuous five‑lead ECG visual monitoring of QTc, frequent blood pressure and pulse oximetry checks and onsite medically trained staff (minimum staff:patient ratio ~1:2) were employed for 12–16 h postdosing. Where judged necessary, a booster dose was administered (one participant received a 4 mg kg‑1 booster ~12 h after the initial dose). Outcome measures and timing: the prespecified primary outcome was change in WHODAS‑2.0 from baseline to immediate posttreatment, with change to 1 month a secondary timepoint. Additional preplanned secondary outcomes were CAPS‑5 (PTSD), MADRS (depression), HAM‑A (anxiety) and a comprehensive neuropsychological battery administered at baseline, posttreatment and 1 month. Neuropsychological scores were converted to T‑scores (mean 50, s.d. 10) for analyses. Statistical analysis used linear mixed‑effects (LME) models with time point as the independent variable (fixed slope, random intercept) and age, CES combat exposure and total number of TBIs included as covariates. False discovery rate (FDR) correction addressed multiple comparisons. Analyses were performed in MATLAB R2021a. Missing data were noted: for example, four participants did not complete the WHODAS at 1 month and varying numbers missed specific neuropsychological tests (detailed in the Methods).

Primary outcome: WHODAS‑2.0 total scores fell from a baseline mean of 30.2 ± 14.7 (classified as mild‑to‑moderate disability) to 19.9 ± 16.3 immediately posttreatment. This decrease was statistically significant (P corrected < 0.001) with an effect size of Cohen's d = 0.74, and all WHODAS subscales showed significant improvement, the largest effect being in the cognition domain (P corrected < 0.001; d = 0.96). At 1 month the WHODAS total score further decreased to 5.1 ± 8.1 (no disability), again highly significant (P corrected < 0.001; d = 2.20). Secondary psychiatric outcomes: LME models indicated statistically significant reductions in CAPS‑5, MADRS and HAM‑A scores immediately post‑MISTIC and at 1 month, with reported effect sizes greater than 2.0 for the clinician‑rated psychiatric assessments. Exploratory responder analyses (excluding one participant who met remission criteria at baseline) found mean percentage reductions of at least 81%, response rates ≥93% and remission rates ≥83% across CAPS‑5, MADRS and HAM‑A. Suicidal ideation assessed via the MADRS SI item decreased from 47% of participants at baseline to 0% immediately posttreatment and 7% at 1 month. Neuropsychological outcomes: objective testing showed statistically significant improvements in processing speed (large effects, d = 0.97–1.34) and in several executive function domains (effect sizes ranging d = 0.31–1.22). Phonemic fluency improved from high average at baseline to superior range at 1 month (d = 1.11). Visual memory improved at both posttreatment timepoints and verbal memory improved by 1 month. Sustained attention accuracy improved with large effects (d = 0.86–1.05), accompanied by a small but significant slowing of reaction time (d = 0.29–0.52), interpreted as prioritisation of accuracy over speed. No test domain showed decline. Safety and adverse events: there were no unexpected or serious treatment‑emergent adverse events, and no instances of clinically detectable bradycardia, tachycardia, clinically meaningful QT prolongation or hemodynamic instability. All participants experienced transient cerebellar signs (mild ataxia, intention tremor) that resolved within 24 h. During the oneirogenic experience, 12 participants (40%) received treatment for headache, 7 (23%) for nausea, 3 (10%) for anxiety, 2 (7%) for hypertension and 1 (3%) for insomnia. Sensitivity analyses: results were robust to subgroup analyses excluding participants who did not meet baseline diagnostic criteria for a given disorder (remission rates at 1 month ≥67%) and to exclusion of participants with non‑mild TBI (remission rates at 1 month ≥85%). Missing data were reported for particular measures (e.g. four participants missing WHODAS at 1 month; several missing CPT‑3 assessments at various timepoints).

Cherian and colleagues interpret their findings as preliminary evidence that a single administration of magnesium‑coadministered ibogaine within the MISTIC protocol was associated with large, clinically meaningful reductions in disability and psychiatric symptoms in SOVs with predominantly mild TBI, with benefits sustained at 1 month. The investigators also report objective improvements on neuropsychological tests—most notably processing speed, executive function and sustained attention—without evidence of cognitive decline, and no serious cardiotoxic or other unexpected adverse events under the clinic's screening and monitoring procedures. The authors position these results alongside prior studies of psychedelic‑assisted approaches that have reported symptomatic improvements in PTSD, depression and substance use, and note that most prior ibogaine research focused on substance use disorders rather than the chronic sequelae of TBI. They also highlight the potential importance of suicidality reductions given elevated suicide risk among veterans. Key limitations are acknowledged: the study was an uncontrolled, open‑label, observational series of self‑selected participants who travelled internationally for treatment, so expectancy, complementary onsite therapies, group activities and other nonspecific factors cannot be excluded as contributors to outcome. The authors note that blinding is particularly difficult in trials of psychedelic medicines given the distinctive phenomenology and duration of ibogaine's effects. Other limitations include the modest, homogeneous sample (30 predominantly white male elite‑unit veterans), the predominance of mild TBI in the sample, incomplete long‑term follow‑up beyond 1 month and potential practice effects on neuropsychological testing despite use of alternative forms and selection of tests with low practice sensitivity. The exploratory finding on suicidality is described as noteworthy but requiring replication with instruments designed specifically for suicidality. Overall, the authors conclude that MISTIC appears tolerable under the conditions described and that magnesium coadministration together with careful screening and monitoring may mitigate previously reported cardiac risks, but they emphasise that randomized, controlled trials and replication in larger and more diverse samples are needed to establish safety and efficacy definitively.